Supplement trials are increasingly built around a placebo-controlled design, and for good reason. Compare outcomes only before and after a product is taken (a single-arm design) and there is no way to separate an effect caused by the product from an effect caused by something else entirely. That something else has a name - the placebo effect. And in supplement research, it turns out to be a considerably bigger factor than many people assume.

What is the placebo effect?
The placebo effect is a real, measurable change that follows an inactive treatment, driven by expectation and context rather than any action by the product or drug tested. Participants are not imagining things or misreporting - their outcomes genuinely change even though nothing biologically active has been given.
This happens for a few well-documented reasons:
- Regression to the mean. People enrol at their worst, so some spontaneous improvement is expected regardless of treatment.
- Expectation. Believing a treatment will help can genuinely change how a person feels and reports their symptoms.
- The ritual of participation. Daily dosing, questionnaires, and check-ins can shape outcomes independent of what is being taken.
What the evidence shows
The scale is easy to underestimate until you see specific cases:
- A recent rose-hip powder trial for osteoarthritis found over 50% improvement in both active and placebo groups. Only by digging into dose-response data, a pattern also seen in two earlier trials, did a genuine effect start to show through [1].
- A review of herbal placebo arms in IBS trials found a 37% average response rate [2].
- In sports nutrition, placebo response has accounted for around 25% of the effect for buffering agents and up to 59% for caffeine [3], for example, cyclists given a placebo they believed was caffeine still raised their power output by up to 2.2% [4].
- Sleep supplements seem particularly susceptible. A meta-analysis of 32 trials found a mean placebo response of 61–64% across both objective and subjective sleep measures [5]. This played out directly in one multi-ingredient sleep nutraceutical trial, where PSQI sleep-quality scores improved by 32.3% in the active group and 39.5% in the placebo group, a difference that wasn't statistically significant, with the "unusually high" placebo response cited as the likely reason [6].
The case for the RCT
Single-arm trials still have a role, particularly for early signal-finding or confirming a product is safe and tolerable before a larger study. But they cannot separate a genuine effect from a placebo effect, and that gap is often too large to ignore. Only a randomised, placebo-controlled design keeps both groups equally exposed to belief, habit, and the ups and downs a condition would show on its own, which is why it remains the standard against which supplement claims are judged.


